Kronos Total Current Liabilities from 2010 to 2024
| KRON Stock | USD 0.87 0.01 1.16% |
Total Current Liabilities | First Reported 2019-09-30 | Previous Quarter 16.6 M | Current Value 15.4 M | Quarterly Volatility 37.3 M |
Check Kronos Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kronos Bio's main balance sheet or income statement drivers, such as Net Interest Income of 9.5 M, Interest Income of 9.5 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 9.18, Dividend Yield of 0.0 or PTB Ratio of 0.48. Kronos financial statements analysis is a perfect complement when working with Kronos Bio Valuation or Volatility modules.
Kronos | Total Current Liabilities |
Latest Kronos Bio's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Kronos Bio over the last few years. Total Current Liabilities is an item on Kronos Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kronos Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Kronos Bio's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kronos Bio's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Kronos Total Current Liabilities Regression Statistics
| Arithmetic Mean | 6,747,690 | |
| Geometric Mean | 3,213,866 | |
| Coefficient Of Variation | 122.71 | |
| Mean Deviation | 7,064,120 | |
| Median | 1,311,000 | |
| Standard Deviation | 8,279,878 | |
| Sample Variance | 68.6T | |
| Range | 23.4M | |
| R-Value | 0.80 | |
| Mean Square Error | 26T | |
| R-Squared | 0.65 | |
| Significance | 0.0003 | |
| Slope | 1,489,512 | |
| Total Sum of Squares | 959.8T |
Kronos Total Current Liabilities History
About Kronos Bio Financial Statements
Kronos Bio investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Kronos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 24.7 M | 14.1 M |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Kronos Stock
| 0.71 | ME | 23Andme Holding | PairCorr |
| 0.71 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Kronos Stock
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Kronos Bio Correlation against competitors. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.